Thirty-six percent had mutations in MSH6 and 39% in MSH2. MSH6 mutation carriers are less likely to meet Amsterdam II criteria [33] and have a lower risk of colorectal cancer (10-22% cumulative risk by 70 years of age) and of other LS-related cancers [34,35]. Here, MSH6 is linked to colorectal cancer.